Cue Biopharma announces proposed public offering

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a new class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it is initiating an underwritten public offering of (or pre-sale of) equity warrants to purchase shares of its common stock in their place) and the accompanying common stock purchase warrants. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering will be completed or as to the actual size and terms of the offering. All securities are offered by Cue Biopharma.

Oppenheimer & Co. acts as the sole book-running manager for the offering. Newbridge Securities Corporation is acting as co-manager for the offering.

A shelf registration statement on Form S-3 (File No. 333-271786) relating to the securities offered in the public offering was filed with the Securities and Exchange Commission (“SEC”) on May 9, 2023 and is effective as of May 26 2023. The offering will be made only by means of a prospectus supplement and the accompanying prospectus that is part of the registration statement. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus, if available, may also be obtained by contacting: Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at (212) 667-8055 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under securities laws applicable in any such state or jurisdiction.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a new class of injectable biologics that selectively recruit and modulate disease-specific T cells directly in the patient’s body. The company’s proprietary Immuno-STAT platform (Selective targeting and alteration of T cells)and biologics aim to harness the healing potential of the body’s internal immune system by selectively modulating disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, our company is led by an experienced management team and an independent Board of Directors with deep expertise in immunology and immuno-oncology, as well as the design and clinical development of protein-based biologics.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those relating to: the proposed public offering, including the completion of the public offering on anticipated terms or at all. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “anticipate”, “believe”, “continue”, “could”, “estimate “, “expect”, “goal”, “intend”, “may”, “plan”, “potential”, “anticipate”, “project”, “seek”, “should”, “target”, “will”, “would” or other comparable terms, although not all forward-looking statements contain these identifying words.

Cue Biopharma may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and, accordingly, you should not place undue reliance on its forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in forward-looking statements made by Cue Biopharma as a result of various risks and uncertainties, including, without limitation, market and other financial conditions, the satisfaction of customary closing conditions relating to the proposed public offering , Cue Biopharma’s limited operating history, limited cash and loss history, Cue Biopharma’s ability to achieve profitability, potential failures in Cue Biopharma’s research and development efforts, including negative or inconclusive results from its preclinical or clinical studies or Cue Biopharma’s ability to replicate in subsequent clinical trials, positive results obtained in preclinical studies and early-stage clinical trials of its product candidates and other risks and uncertainties described in the Risk Factors and Management Discussion and Analysis of Financial Condition and Results of Operations sections of Cue Biopharma’s most recently filed Annual Report on Form 10 -K and any subsequent quarterly reports on Form 10-Q. Any forward-looking statements made by Cue Biopharma in this press release are based solely on information currently available to Cue Biopharma and speak only as of the date on which they are made. Cue Biopharma undertakes no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time as a result of new information, future developments or otherwise.

Contact for investors
Maria Campinell
Senior Director of Corporate Communications
Cue Biopharma, Inc.
[email protected]

Contact with the media
Jonathan Pappas
LifeSci Communications
[email protected]